[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glomerular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glomerular-diseases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100282275","iga-nephropathy-biomarkers-evaluation-study-interest-100282275",false,"NCT02954419","IgA Nephropathy Biomarkers Evaluation Study (INTEREST)","INTEREST","Inclusion Criteria:\n\n* Male or female individuals aged 14 years or older\n* Patients with biopsy-proven primary IgA nephropathy\n* A renal biopsy available for reviewing must include 10 or more glomeruli.\n* The first renal biopsy was performed within 3 years.\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73 m2 (MDRD formula);\n* Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Relatives were diagnosed with biopsy-proven primary IgA nephropathy;\n* Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.","ALL","14 Years",{"count":19,"type":20},2000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml\u002Fmin\u002F1.73 m2).",[24,25],"IgA Nephropathy","Glomerular Diseases",[24,27],"Biomarker","RECRUITING","2026-04-08",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":4},"2016-11",{"date":36,"type":20},"2027-01",{"name":38,"class":39},"Sun Yat-sen University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100503750","phase-4-effect-of-huaier-granule-on-the-treatment-of-idiopathic-membranous-nephropathy-100503750","NCT05839314","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy: a Multicenter, Randomized, Open-label, Parallel Controlled Study","Inclusion Criteria:\n\n* Renal biopsy was performed before randomization and pathologically diagnosed as idiopathic membranous nephropathy;\n* Anti-phospholipase a2 receptor (PLA2R) antibody is positive;\n* Aged from 18 to 75, either sex;\n* Tolerable doses of RASI were received for ≥4 weeks before randomization, nephrotic syndrome was not in remission and 24-hour urinary protein level was ≥3.5g\u002F24h and \\\u003C 8.0g\u002F24h;\n* The eGFR≥45ml\u002Fmin\u002F1.73m2 (Measured at least twice in 2 weeks);\n* The patient is willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed as secondary membranous nephropathy;\n* Rapidly progressive membranous nephropathy (eGFR decreased by 50 % compared with the baseline level within 3 months);\n* Receiving renal replacement therapy;\n* Diabetes and glycosylated hemoglobin (HbA1c) levels ≥ 7.0%;\n* Hypertension is not well controlled (systolic blood pressure\\>160mmHg or diastolic blood pressure\\>100mmHg);\n* The level of serum albumin≤20g\u002FL;\n* Resistance to treatment with CsA or other CNI, rituximab (RTX) or alkylating agents; complete remission or partial remission was obtained after treatment with CNI, RTX, or alkylating agents but there was a history of relapse within 3 months；\n* Suspected infection by imaging and\u002For laboratory tests;\n* Infectious diseases, such as hepatitis B, hepatitis C, AIDS, tuberculosis;\n* History of malignant tumor;\n* Hepatic dysfunction: aspartate aminotransferase (AST) concentration and alanine aminotransferase (ALT) concentration of \\> 1.5 × upper limit of normal;\n* Allergic to Huaier granule or Ciclosporin soft capsules;\n* Previous CNI treatment was ineffective;\n* Complicate with any diseases that may affect efficacy and safety evaluation;\n* Pregnant or lactating women, and patients (male or female) with fertility plans or unwilling to take effective contraceptive measures;\n* Participating in other clinical trials or participated in other clinical studies within 3 months;\n* According to the researchers, patients have diseases or conditions that increase the difficulty of enrollment or probability of loss to follow-up, such as mental illness, frequent changes in residence and work, etc.","18 Years","75 Years",{"count":51,"type":20},480,"INTERVENTIONAL",[54],"PHASE4","This is a prospective, multicenter, randomized, open-label, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier granule on the treatment of idiopathic membranous nephropathy comparing with Ciclosporin soft capsules.",[57,25,58],"Nephropathy","Idiopathic Membranous Nephropathy",[60,61,62],"Huaier granule","Ciclosporin","Idiopathic membranous nephropathy","2024-06-02",{"date":65,"type":32},"2024-06-04",{"date":67,"type":32},"2023-05-09",{"date":69,"type":20},"2027-07-01",{"name":71,"class":39},"Chinese PLA General Hospital"]